The Avience Biomedicals SME IPO was subscribed 354.99 times in total when bidding closed on 22 June 2026. The issue closed oversubscribed, so allotment in the oversubscribed categories was by lottery for retail and proportionate for institutions and non-institutional investors.
| Day | Retail | Total | sHNI | QIB | bHNI | NII |
|---|---|---|---|---|---|---|
| Day 1 (18 June 2026) | 15.36× | 10.59× | 13.10× | — | 13.66× | 13.48× |
| Day 2 (19 June 2026) | 58.50× | 43.62× | 66.67× | 0.03× | 66.67× | 66.67× |
| Day 3 (22 June 2026) | 401.21× | 385.33× | 451.32× | 196.77× | 670.77× | 597.62× |
354.99 times overall. The figure is the shares bid for divided by the shares offered in that category, from the exchanges' cumulative bid data.
Yes, 354.99 times overall. Above one time, applicants in that category are not guaranteed shares.
Qualified institutional buyers are mutual funds, insurers, banks and foreign institutions. Non-institutional investors, also called HNI, are individuals and bodies bidding above two lakh rupees, split into small (two to ten lakh) and big (above ten lakh). Retail is an individual bidding up to two lakh rupees. An SME issue sets aside at least 35 percent of the offer for retail and 15 percent for NII after the market maker's portion.
No. Subscription measures demand during the three bidding days; the listing price is discovered in the pre-open session on listing morning and depends on the market that day. Heavily subscribed issues have listed at a discount and thin ones at a premium. Read the figure with the expected premium and the company's numbers, not instead of them.
23 June 2026. The allotment status is searchable by PAN on Rupix and on the registrar's page from that evening.